Literature DB >> 18430624

Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia.

Ellen B Fung1, Paul R Harmatz2, Meredith Milet3, Thomas D Coates4, Alexis A Thompson5, Mark Ranalli6, Robert Mignaca7, Charles Scher8, Patricia Giardina9, Shanda Robertson10, Lynne Neumayr10, Elliott P Vichinsky10.   

Abstract

Transfusional iron overload leads to gonadal failure and low bone mass in patients with thalassemia (Thal). However, gonadal failure is rarely reported in transfused patients with sickle cell disease (SCD) and the literature regarding fracture prevalence in SCD is limited. The objective of this study was to assess self-reported fracture prevalence and its relationship to endocrinopathy in transfused Thal or SCD subjects and compare to non-transfused subjects with SCD (NonTxSCD). Eligibility was based on age> or =12 years and liver iron concentration> or =10 mg/g dry wt or serum ferritin> or =2000 ng/mL (Thal or TxSCD) or for NonTxSCD, ferritin<500 ng/mL. Data were collected by patient interview and chart review at 31 clinical centers in the U.S., Canada and the U.K. 152 subjects with Thal (52% Male; 25.6+/-0.7 years), 203 subjects with TxSCD (44% Male, 24.7+/-0.9 years: Mean+/-SE), and 65 NonTxSCD (50% Male, 22.2+/-1.3 years) were enrolled. Overall, male subjects with Thal were more likely to have sustained a fracture in their lifetime (51%) compared to TxSCD (28%) or NonTxSCD (32%) (p=0.005). There was no difference in fracture prevalence among women (Thal: 26%, TxSCD 17%, NonTxSCD: 16%). Fracture was most frequently reported in the upper extremities (53.3% of all fractures) while spine and pelvic fractures were relatively common for such a young cohort: 10.6%. Though overall fracture prevalence was not distinctly different from published healthy cohorts, fewer fractures occurred during the adolescent years. In multivariate analysis, the significant predictors of fracture prevalence were Thal diagnosis (Odds Ratio: 2.3; 1.2-4.6; 95%CI), male gender (OR: 2.6; 1.5-4.5), hypothyroidism (OR: 3.3; 1.1-9.8) and age (OR: 1.1; 1.03-1.08). These data suggest that despite similar iron burden, transfused patients with Thal are at greater risk for fracture than subjects with SCD. Male subjects with Thal and hypothyroidism are at particular risk for fracture, in contrast, transfused subjects with SCD had no greater risk of fracture compared to non-transfused SCD. Though ethnic differences in fracture risk cannot be ignored, endocrinopathy is rare in TxSCD which may also provide some protection from fracture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430624      PMCID: PMC2500183          DOI: 10.1016/j.bone.2008.03.003

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  32 in total

1.  Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.

Authors:  V De Sanctis; S Stea; L Savarino; V Scialpi; G C Traina; G M Chiarelli; M Sprocati; R Govoni; D Pezzoli; R Gamberini; F Rigolin
Journal:  J Pediatr Endocrinol Metab       Date:  1998       Impact factor: 1.634

2.  Serum zinc and its relation to bone mineral density in beta-thalassemic adolescents.

Authors:  Mir Reza Bekheirnia; Alireza Abdollah Shamshirsaz; Mohammad Kamgar; Navid Bouzari; Ghazaleh Erfanzadeh; Nima Pourzahedgilani; Seyed Mahmood Tabatabaie; Amirhooshang Abdollah Shamshirsaz; Masood Kimiagar; Fatemeh Ezzati; Bagher Larijani
Journal:  Biol Trace Elem Res       Date:  2004-03       Impact factor: 3.738

3.  Adequacy of dietary intake declines with age in children with sickle cell disease.

Authors:  Deborah A Kawchak; Joan I Schall; Babette S Zemel; Kwaku Ohene-Frempong; Virginia A Stallings
Journal:  J Am Diet Assoc       Date:  2007-05

4.  Prevalence of fractures among the Thalassemia syndromes in North America.

Authors:  M G Vogiatzi; E A Macklin; E B Fung; E Vichinsky; N Olivieri; J Kwiatkowski; A Cohen; E Neufeld; P J Giardina
Journal:  Bone       Date:  2005-11-17       Impact factor: 4.398

Review 5.  Bone and joint disease in sickle cell disease.

Authors:  Christine Aguilar; Elliott Vichinsky; Lynne Neumayr
Journal:  Hematol Oncol Clin North Am       Date:  2005-10       Impact factor: 3.722

6.  Epidemiology of children's fractures.

Authors:  L A Landin
Journal:  J Pediatr Orthop B       Date:  1997-04       Impact factor: 1.041

7.  Sickle cell morbidity profile in Omani children.

Authors:  F Jaiyesimi; R Pandey; D Bux; Y Sreekrishna; F Zaki; N Krishnamoorthy
Journal:  Ann Trop Paediatr       Date:  2002-03

8.  Pathological fracture complicating long bone osteomyelitis in patients with sickle cell disease.

Authors:  W W Ebong
Journal:  J Pediatr Orthop       Date:  1986 Mar-Apr       Impact factor: 2.324

9.  Sickle cell anaemia: is it a cause for secondary osteoporosis?

Authors:  M Sadat-Ali; A H Al Elq
Journal:  West Afr J Med       Date:  2007 Apr-Jun

10.  [Stress fracture of the femur: a rare complication of sickle cell disease].

Authors:  J Bahebeck; M Ngowe Ngowe; M Monny Lobe; M Sosso; P Hoffmeyer
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  2002-12
View more
  23 in total

1.  Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI.

Authors:  Ellen B Fung; Jo Ann Johnson; Jacqueline Madden; Tiffany Kim; Paul Harmatz
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 2.  Musculoskeletal imaging manifestations of beta-thalassemia.

Authors:  Maryam Hajimoradi; Sara Haseli; Alireza Abadi; Majid Chalian
Journal:  Skeletal Radiol       Date:  2021-02-09       Impact factor: 2.199

3.  Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease.

Authors:  Kristen M Williams; Margaret T Lee; Maureen Licursi; Gary M Brittenham; Ilene Fennoy
Journal:  J Pediatr Hematol Oncol       Date:  2018-08       Impact factor: 1.289

4.  Vertebral Bone Density Measurements by DXA are Influenced by Hepatic Iron Overload in Patients with Hemoglobinopathies.

Authors:  Haven M Allard; Lisa Calvelli; Marcela G Weyhmiller; Ginny Gildengorin; Ellen B Fung
Journal:  J Clin Densitom       Date:  2018-07-11       Impact factor: 2.617

Review 5.  Dual-energy X-ray absorptiometry pitfalls in Thalassemia Major.

Authors:  Fabio Pellegrino; Maria Chiara Zatelli; Marta Bondanelli; Aldo Carnevale; Corrado Cittanti; Monica Fortini; Maria Rita Gamberini; Melchiore Giganti; Maria Rosaria Ambrosio
Journal:  Endocrine       Date:  2019-07-12       Impact factor: 3.633

6.  Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo.

Authors:  Lei Wang; Bin Fang; Toshifumi Fujiwara; Kimberly Krager; Akshita Gorantla; Chaoyuan Li; Jian Q Feng; Michael L Jennings; Jian Zhou; Nukhet Aykin-Burns; Haibo Zhao
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

Review 7.  The management of osteoporosis in children.

Authors:  L M Ward; V N Konji; J Ma
Journal:  Osteoporos Int       Date:  2016-04-28       Impact factor: 4.507

Review 8.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

Review 9.  Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Authors:  Andrea Giusti
Journal:  J Bone Miner Metab       Date:  2014-04-21       Impact factor: 2.626

Review 10.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.